Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

BPC-157 vs GHK-Cu

Comparison

BPC-157 and GHK-Cu are two peptides people frequently compare. BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most… GHK-Cu is a copper peptide widely used in skincare for wound healing, skin rejuvenation, and anti-aging. It works by delivering copper to skin cells and activating the processes the body uses to…

BPC-157 GHK-Cu
What it is BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most… GHK-Cu is a copper peptide widely used in skincare for wound healing, skin rejuvenation, and anti-aging. It works by delivering copper to skin cells and activating the processes the body uses to…
Primary uses
  • Interstitial cystitis (bladder pain syndrome)
  • Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone)
  • Wound healing (skin, gastrointestinal, and other tissues)
  • Gastrointestinal anastomosis healing and fistula therapy
  • Wound healing and skin repair
  • Anti-aging and skin rejuvenation (topical/cosmeceutical)
  • Anti-inflammatory and antioxidant effects
  • Skeletal muscle dysfunction / COPD-related sarcopenia
How it works It's also used for gut inflammation and ulcer healing. Not FDA-approved; most research is in animals, with a few small human studies. It works by delivering copper to skin cells and activating the processes the body uses to repair and rebuild tissue. Not FDA-approved as a drug; extensively used in cosmetics and widely studied.
Common dose 250 mcg, subcutaneous injection, once daily 1-2 mg, subcutaneous injection, daily
FDA status Not approved by the US Food and Drug Administration for any therapeutic indication (PMID: 39325560, PMID: 40005999, PMID: 42198317). No completed Phase II clinical trial as of the reviewed literature. Not FDA-approved as a drug; most applications remain unapproved. Multiple review articles note GHK-Cu is not FDA-approved and lacks rigorous clinical trial validation. One review notes GHK-Cu is…
Evidence level Human observational Mixed